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Abstract
Background and purpose: The purpose of this study was to determine the distribution of 4-borono-2-18F-fluoro-
phenylalanine (18F-BPA) and L-[methyl-11C] methionine (11C-Met) in normal organs and tumors and to evaluate the
usefulness of 11C-Met/PET in screening potential candidates for boron neutron capture therapy (BNCT).
Material methods: Seven patients who had at least one histologically confirmed head and neck tumor were
included in this study. They underwent both whole-body 18F-BPA-PET/CT and 11C-Met-PET/CT within a span of
6 months. Uptake was evaluated using the maximum standardized uptake value (SUVmax). Regions of interest
(ROIs) were placed within the tumors and target organs of brain, thyroid, submandibular gland, lung, liver,
esophagus, stomach pancreas, spleen, muscle, and bone marrow.
Results: The tumor SUVmax of FBPA and 11C-Met showed strong correlation (r2 = 0.72, P = 0.015). Although 18F-BPA
and 11C-Met showed markedly different uptake in some organs (submandibular gland, liver, heart, stomach pancreas,
spleen, and bone marrow), the uptake of 11C-Met was consistently higher than that of 18F-BPA in these cases.
Conclusion: 11C-Met PET/CT might be used instead of 18F-BPA PET/CT to predict the accumulation of 10B in tumors
and to select candidates for BNCT. However, it would not be suitable for evaluating accumulation in some normal
organs. Therefore, the 18F-BPA-PET study remains a prerequisite for BNCT. This is the first report of the correlation
between 18F-BPA and 11C-Met accumulation.
Background
Boron neutron capture therapy (BNCT) has recently
attracted attention and has been used for brain tumors,
head and neck cancers, and melanoma [1–4]. It is a
targeted radiotherapy method, based on the nuclear
reaction of neutrons and 10B. After the injection of a 10B
carrier, it accumulates in target tumor cells. The region
to be treated is then exposed to thermal neutrons, and
the nuclear reaction of these neutrons with 10B produces
alpha particles and 7Li at very short range (<10 μm),
causing lethal damage to tumor cells. The success of
BNCT is dependent on the sufficient accumulation of
10B in tumor cells and the minimization of such
accumulation in normal cells [1, 2, 5]. 10B accumulation
is not consistent across cases, and is reported to depend
upon tumor type. However, even tumors of the same
grade may differ in terms of their biochemical proper-
ties. Therefore, it is necessary to assess 10B accumulation
in each case prior to performing BNCT [6].
10B-borono-L-phenylalanine (BPA) is the most frequently
used 10B carrier, and 18F-BPA, an 18F-labelled analog of
BPA, has been developed to predict 10B accumulation in
tumors and normal tissues by positron emission tomog-
raphy (PET) [7, 8]. Before BNCT, a 18F-BPA-PET study is
carried out to evaluate the tumor-to–normal tissue accu-
mulation ratio (TNR). The TNR strongly influences the
success of BNCT, and the ideal TNR has been reported to
be greater than 2.5 to 5 [1, 5]. However, the synthesis of
18F-BPA, a radiolabeled amino acid, is limited due to low
radio yield, low synthetic yield, and high cost. Therefore
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few hospitals or institutions can synthesize 18F-BPA in
practice [9].
11C -labelled Methionine (11C-Met) is the most popu-
lar radiolabeled amino acid. Methionine is an essential
amino acid and plays an important role in protein
synthesis as it is coded for by the initiation codon. Radi-
olabeled methionine is a convenient radiochemical prod-
uct because it can be obtained by rapid synthesis with
high radiochemical yield [10]. 11C-Met is a highly sensi-
tive tool capable of yielding considerable information on
protein synthesis, and has been used widely in the
assessment of various cancers [11, 12]. Compared to
18F-fluorodeoxyglucose, 11C-Met shows low uptake in
the brain, so 11C-Met PET can evaluate head and neck
tumors without interference from physiological accumu-
lation in the brain [13, 14].
In this study, we evaluated the distribution of these
two radiolabeled amino acids, 18F-BPA and 11C-Met, in
patients with head and neck tumors, in order to evaluate
whether 11C-Met PET can be used instead of 18F-BPA
PET for screening potential candidates for BNCT.
Materials and methods
General
All chemical reagents were obtained from commercial
sources. This study was conducted according to a proto-
col approved by the institutional review board/independ-
ent ethics committee of the National Cancer Center
Hospital (Tokyo, Japan). All patients signed a written in-
formed consent form before the initiation of the study.
Radiosynthesis of 18F-BPA and 11C-MET
18F-BPA was synthesized by direct electrophilic radio-
fluorination of BPA (Sigma-Aldrich, St. Louis, MO,
USA) using 18F-acetyl hypofluorite as described previ-
ously [6]. Purification of 18F-BPA was performed by high
performance liquid chromatography (HPLC) using a
YMC-Pack ODS-A column (20 × 150 mm; YMC, Kyoto,
Japan) eluted with 0.1% acetic acid at a flow rate of
10 ml/minute. The radiochemical purity of 18F-BPA as
determined by HPLC was > 99.5%, while its specific ac-
tivity was 25 MBq/μmol.
11C-Met was synthesized in the radiochemical labora-
tory of this institute by methylation with L-homocysteine
thiolactone followed by isolation of the final product by
solid phase extraction using L-homocysteine thiolactone
(Sigma-Aldrich, St. Louis, MO, USA) [10]. The radio-
chemical purity of 11C-Met ranged from 95 to 98%.
Subjects
The seven patients included in this study underwent both
18F-BPA-PET/computed tomography (CT) and 11C-Met-
PET/CT at least 24 h apart, but within 6 months of each
other, between January 2014 and July 2016. Of the 116
patients who underwent 18F-BPA PET/CT, seven also
underwent 11C-Met-PET/CT. These seven patients were
retrospectively selected for this study. They had histologi-
cally confirmed head and neck tumors, Eastern Coopera-
tive Oncology Group performance status (PS) of 0–1,
adequate organ function (neutrophil count ≥ 1500 /μL,
platelet count ≥ 75,000 /μL, hemoglobin concentration ≥
9.0 g/dL, serum bilirubin ≤1.5 mg/dL, aspartate trans-
aminase (AST) and alanine aminotransferase (ALT) ≤
100 IU/L, serum creatinine ≤ 1.5 mg/dL, baseline left ven-
tricular ejection fraction (LVEF) > 60%), and were older
than age 20. For evaluating the distribution of 11C-Met
and 18F-BPA in normal organs, we excluded patients with
congestive heart failure, uncontrolled angina pectoris,
arrhythmia, symptomatic infectious disease, severe bleed-
ing, pulmonary fibrosis, obstructive bowel disease or
severe diarrhea, and symptomatic peripheral or cardiac
effusion.
Patients fasted for at least 4 h before examination.
PET/CT protocol
PET/CT images were acquired with a Discovery 600
scanner (GE Healthcare, Milwaukee, WI, USA). Whole-
body 18F-BPA PET/CT imaging was carried out at 1 h
after the injection of 18F-BPA (ca. 4 MBq/kg). The scan
timing for 18F-BPA PET/CT was determined as in our
previous work [6]. Whole-body 11C-Met PET/CT was
carried out 10 min after the injection of 11C-Met (ca.
4 MBq/kg). The scan timing for11C-Met PET/CT was
determined by a previous report [15]. A scout image was
first acquired to determine the scanning field range from
the head to the pelvis of the patient, using settings of
10 mA and 120 kV. Next, whole-body 16-slice helical
CT and whole-body 3D PET were performed. PET
images were acquired in 7–8 bed positions with 2-min
acquisition durations per bed position, such that the
images covered the same field as the whole-body CT
image. The acquired data were reconstructed as 192 ×
192 matrix images (3.65 × 3.65 mm) using a 3D ordered
subsets-expectation maximization algorithm.
Tumor uptake of 18F-BPA and 11C-Met
PET image evaluation and quantification of the stan-
dardized uptake value (SUV) were performed using AW
Volume Share 4.5 software (GE Healthcare, Milwaukee,
WI, USA). Regions of interest (ROIs) were delineated on
the axial 2-D image. SUV was defined as regional radio-
activity divided by injected radioactivity normalized to
body weight. 18F-BPA uptake was evaluated using the
maximum SUV (SUVmax) 1 h after injection, while 11C-
Met uptake was evaluated 10 min after injection. ROIs
were placed within the tumor and target organs of brain
(white matter), thyroid, submandibular gland, lung, liver,
esophagus (cervical esophagus), stomach, pancreas, spleen,
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muscle (latissimus dorsi), and bone marrow (12th thoracic
vertebra). Tumor ROIs were defined as the areas of high-
est activity. ROIs were also placed onto normal tissue sur-
rounding the tumor to calculate the TNR of 18F-BPA.
Clinically, dose planning is performed based on the TNR
prior to the initiation of BNCT to avoid severe damage to
normal tissues.
Statistical analysis
For statistical analysis of the data, JMP software (version
9.0, SAS Institute, Inc., Cary, NC) was used. A linear re-
gression analysis was performed for the correlation study.
Fisher’s exact test was used to estimate the concordance
of the cut-off values of the two tracers. Probability values
of P < 0.05 were considered significant. Since patients in
previous studies were determined to be eligible for BNCT
when the TNR of 18F-BPA was more than 2.5 [1, 6, 8, 16],
we used a 18F-BPA TNR of more than 2.5 as a cut-off to
distinguish positive from negative.
Results
Seven patients with head and neck tumors underwent
both 18F-BPA-PET/CT and 11C-Met-PET/CT during the
study period and were enrolled in this study (six males
and one female; ages 20 to 66 years, median 47 years).
Patient and tumor characteristics are summarized in
Table 1. In terms of the primary disease type, two pa-
tients had facial rhabdomyosarcoma, one had external
auditory canal cancer, one had lingual cancer, one had
malignant melanoma of the nasal cavity, one had parotid
gland cancer, and one had adenoid cystic carcinoma of
the lacrimal sac. Histological diagnoses included two pa-
tients with squamous cell carcinoma (SCC), two with
adenoid cystic carcinoma (ACC), two with rhabdomyo-
sarcoma (RBD), and one with malignant melanoma.
Four patients experienced local recurrence (LR), one had
distant metastases, and two had a newly diagnosed sec-
ond malignancy. All patients had unresectable tumors.
All lesions were located within the head and neck region
(two lesions in the maxillary sinus, one in the external
auditory canal, one in the nasal cavity, one in the tongue,
one in the parotid gland, and one in the orbit). Tumor
size scaled by PET/CT ranged from 2 to 5 cm. The
tumor size did not change in the interval between PET
scans in six cases, but in one case (No. 1) the tumor
grew from 3 cm to 5 cm. Five patients underwent sur-
gery and received radiotherapy and chemotherapy within
1 year before the PET scans, while two patients did not
receive any treatment before the scans. Neither chemo-
therapy nor radiation therapy was performed in any pa-
tient in the interval between PET scans, but one patient
(No. 1) underwent palliative surgery during this time.
However, in case No. 1 the target tumor was almost
unresectable and we were able to evaluate radioisotope
accumulation in the tumor tissue. In four cases, 18F-
BPA-PET/CT was performed prior to 11C-Met-PET/CT.
In the remaining three cases, 18F-BPA-PET/CT was per-
formed after 11C-Met-PET/CT. The interval between
studies was less than 3 weeks in six cases, and more than
3 months in one case (No. 1). The interval ranged from
2 to 123 days (mean, 23 ± 41; median, 5).
Representative PET/CT imaging of 18F-BPA and 11C-
Met is shown in Fig. 1. SUVmax values of 18F-BPA and
11C-Met in tumor tissue are summarized in Table 1. The
accumulations of 18F-BPA and 11C-Met varied widely
among tumor cases, even in those with the same path-
ology. The tumor SUVmax of 18F-BPA ranged from 1.6
to 5.6 (mean, 3.9 ± 1.4), while that of 11C-Met ranged
from 1.5 to 5.8 (mean, 4.6 ± 1.7). The TNRs of both
18F-BPA and 11C-Met also varied widely. The TNR of
Table 1 Patient and tumor characteristics
No. Sex Age Primary
disease
Presentation Histology Location Past
therapy
Size (cm) Interval between
studies (days)
Tumor SUVmax Tumor TNR
11C-Met 18F-BPA 11C-Met 18F-BPA
1 M 20 Facial RBD NT RBD orbit Noa 3.2 × 3.0
to 4.5 × 5.0b
123 3.7 3.6 3.8 3.9
2 M 20 Facial RBD LR RBD MS PO/CRT 2.5 × 1.5 5 1.5 1.6 1.1 1.3
3 M 27 Lingual LR SCC Lingual PO/CRT 3.2 × 4.1 16 6.6 4.2 4.6 3.1
4 M 50 EAC cancer LR SCC EAC PO /CRT 3.3 × 4.4 2 4.4 4.1 3.1 2.9




PO /CRT 2.0 × 2.3 2 5.6 5.6 5.1 2.7




No 3.1 × 3.2 4 5.8 4.7 4.1 3.9











RBD rhabdomyosarcoma, EAC external auditory canal, ACC adenoid cystic carcinoma, NT newly diagnosed tumor, LR local recurrence, M Metastasis, SCC squamous
cell carcinoma, MS maxillary sinus, PO postoperative, CRT chemoradiation therapy
aPalliative surgery was performed in the interval between PET scans. bTumor size increased in the interval between PET scans
Watanabe et al. Radiation Oncology  (2017) 12:17 Page 3 of 7
18F-BPA ranged from 1.3 to 3.9 (mean, 2.9 ± 0.9), while
that of 11C-Met ranged from 1.1 to 5.1 (mean, 3.4 ± 1.4).
The TNRs of 18F-BPA and 11C-Met were weakly corre-
lated (r2 = 0.51), though statistical significance was not
observed (P = 0.07). However, the SUVmax of 18F-BPA
and 11C-Met within each tumor exhibited strong correl-
ation (Fig. 2; r2 = 0.72, P = 0.015).
Accumulations of 11C-Met and 18F-BPA in normal
organs are summarized in Table 2. As expected,
accumulations of 18F-BPA in normal organs showed
smaller differences between patients than accumulations
in tumors.
Across all patients, the uptake of 18F-BPA and 11C-
Met differed widely in the submandibular gland, liver,
heart, stomach, pancreas, spleen, and bone marrow. In
these organs, the uptake of 11C-Met was consistently
higher than that of 18F-BPA. In all other organs, no
significant difference was observed.
Discussion
It is well-known that accumulation of radioisotopes is
affected by nature of tumors [17, 18]. In most cases in
this study, PET/CTs were performed as preparation for
therapy and the intervals between scans were less than
3 weeks. However, in one case (No. 1), the interval be-
tween 18F-BPA-PET/CT and 11C-Met-PET/CT was more
than 3 months; palliative surgery was performed during
the interscan interval, although the target tumor was
almost unresectable. The long interval and palliative op-
eration may have affected the results in this case.
However, excluding the single long-interval case, the
TNRs of 18F-BPA and 11C-Met showed a weak correl-
ation (r2 = 0.57 P = 0.08), and the SUVmax of 18F-BPA
and 11C-Met within each tumor were strongly correlated
(r2 = 0.73, P = 0.03). As a result, we do not believe that the
interscan interval or the palliative operation particularly
influenced the results of this study. On the other hand,
five patients underwent surgery and received radio-
therapy and chemotherapy within 1 year before the
PET scans, and it is unclear whether this treatment
influenced our results.
Radiolabeled amino acids are among the most import-
ant tracers for identifying and examining tumors, since
cellular proliferation requires protein synthesis. Amino
acids are the natural building blocks of proteins, and
high uptake of these precursors is a normal feature of
rapidly proliferating cells such as tumor cells. Tumor
cells take up amino acids by amino acid transporters,
thus the numbers of such transporters is increased in
most tumor types as compared to healthy tissue [19].
Studies have shown that there are a variety of amino
acid transporters, such as System L, System A, System
ASC, and System B [9, 20], and 18F-BPA is a System L–
specific imaging agent [9]. System L is Na+-independent
and is a major nutrient transport system responsible for
the transport of neutral amino acids. System L includes
four families, LAT1–LAT4.
18F-BPA uptake correlates with total LAT expression,
but more specifically with that of LAT1 and LAT4, which
are overexpressed in many tumors [9, 21–23]. On the
other hand, 11C-Met is taken up not only by System L, but
also by many other types of amino acid transporter such
as System A, System ASC, and System B [20, 24, 25]. It
has been previously reported that the expression of amino
acid transporters in tumors varies widely, and it some-
times reflects proliferation speed and malignancy [26].
This may explain the wide variation in the tumor accumu-
lation of 18F-BPA and 11C-Met in this study, regardless of
pathology. Despite the fact that 11C-Met and 18F-BPA are
affected by different amino acid transporters, we found
that 11C-Met uptake correlated closely with 18F-BPA up-
take. One possible explanation is that the rates of amino
acid transport and protein synthesis are so rapid that
differences in the types of amino acid transporter may not
be significant. Further studies with larger numbers of par-
ticipants and comparison of particular histological features
should be performed to resolve this question.
Fig. 1 Representative 11C-Met and 18F-BPA PET/CT (patient No. 6).
Upper panel: maximum intensity projection imaging. Lower panel:
PET/CT fusion image. a 11C-Met-PET/CT at 10 min after injection.
Tumor SUVmax was 5.8. (*). High physiological uptake is shown in
the salivary glands (arrows), bone marrow, and some abdominal
organs. b 18F-BPA-PET/CT at 1 h after injection. Tumor SUVmax was
4.7. (*). Physiological uptake is generally low
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In normal organs, we found that accumulation differed
between 11C-Met and 18F-BPA in the submandibular
gland, liver, heart, stomach, pancreas, spleen, and bone
marrow, whereas it was similar in all other normal
organs. Previous papers have also reported similar ten-
dencies in 11C-Met distribution [15] . The uptake of
11C-Met and 18F-BPA in normal organs showed smaller
individual differences than in tumors. The variation in
relative accumulation between tumors and healthy or-
gans may be attributed to the histological heterogeneity
of tumors. Similarly, there was no significant difference
between accumulations in brain, thyroid, lung, esophagus,
and muscle. These organs had insufficient accumulations
of both 11C-Met and 18F-BPA to reveal any difference,
perhaps because there is less protein synthesis and cell
proliferation in these organs, making the uptake of the
amino acids themselves very low.
On the other hand, some normal organs showed
higher uptake of 11C-Met than of 18F-BPA. This differ-
ence was especially pronounced in organs with high
levels of protein synthesis or cell proliferation, such as
the submandibular gland, pancreas, liver, stomach, and
bone marrow. The heart produces several hormones,
such as brain natriuretic peptide. The spleen sometimes
has extramedullary hematopoietic functions in cases
Fig. 2 Correlation of SUVmax between 18F-BPA and 11C-Met in head and neck tumors. A close linear correlation is observed between FBPA uptake
and MET uptake in head and neck tumors (r2 = 0.72, P = 0.15)
Table 2 Average and standard deviation (SD) of 18F-BPA and
11C-Met uptake in normal organs
11C-Met 18F-BPA P value
Brain 1.5 ± 0.1 1.3 ± 0.3 0.31
Submandibular gland 5.2 ± 1.2 2.0 ± 0.5 <<0.01
Thyroid gland 2.1 ± 0.4 1.4 ± 0.5 0.7
Esophagus 2.3 ± 0.6 1.9 ± 0.6 0.18
Lung 0.7 ± 0.1 0.6 ± 0.2 0.76
Heart 2.5 ± 0.4 1.2 ± 0.1 <<0.01
Blood 1.5 ± 0.2 1.3 ± 0.1 0.07
Stomach 8.8 ± 2.6 1.5 ± 0.2 <<0.01
Liver 11 ± 1.8 2.0 ± 0.5 <<0.01
Pancreas 12.6 ± 2.8 1.7 ± 0.3 <<0.01
Spleen 3.1 ± 0.6 1.5 ± 0.3 <<0.01
Kidney 4.0 ± 0.4 3.4 ± 0.9 0.18
Muscle 1.3 ± 0.1 1.2 ± 0.2 0.21
Bone marrow 3.8 ± 0.8 1.5 ± 0.3 <<0.01
Tumor 4.6 ± 1.7 3.9 ± 1.2 0.39
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where the bone marrow has been damaged. Thus both
organs can be considered to be involved in protein syn-
thesis. Although these organs all require amino acids to
synthesize proteins, the pancreas, liver, stomach, heart,
and submandibular gland do not express LAT1 or
LAT4, while the bone marrow and spleen express LAT1
but not LAT4 [27, 28]. These latter organs may exhibit
less 18F-BPA uptake because is transported mainly by
LAT1 and LAT4 [9]. As mentioned, 11C-Met can be
transported by many types of amino acid transporter
[9, 20], including System A, expressed by the stomach,
liver, pancreas, heart, and spleen [29], and System B (0,+),
expressed by the salivary glands [30]. This could explain
the fact that the accumulation of 11C-Met in these organs
was higher than that of 18F-BPA, and it may be that vari-
ation in the distribution of amino acid transporters causes
differences in uptake. In other words, the greater accumu-
lation of 11C-Met may suggest that its uptake reflects
protein synthesis more generally, whereas the uptake of
18F-BPA also reflects the expression of LAT1 and LAT4.
Our study also revealed a low physiological accumula-
tion of 18F-BPA in normal organs. This may be of great
advantage, not only in the evaluation of 10B accumula-
tion, but in tumor detection. It could be especially useful
when evaluating tumors in the liver, the pancreas, or
stomach. In particular, a study on bile duct carcinoma,
including pancreatic cancer, found that the expression of
LAT 1 correlated positively with degree of malignancy
[26], thus the accumulation of 18F-BPA might predict
the malignancy of these cancers.
Our findings suggest that the accumulation of 11C-Met
may predict the accumulation of 18F-BPA in tumors.
Nevertheless, for success of BNCT, performance of the
TNR is more important than evaluation of SUVmax [1, 5].
In all cases where the tumor TNR of 11C-Met was posi-
tive, the tumor TNR of 18F-BPA was also positive. How-
ever, the correlation between the TNRs of 18F-BPA and
11C-Met was not statistically significant. It is inferred that
the accumulation in normal tissues surrounding the
tumor differed between 18F-BPA and 11C-Met. In this
study, as the organs demonstrating high uptake of 11C-
Met were located far from the tumors, or post resection,
we were able to a certain extent to evaluate the TNR by
11C-Met PET/CT. However, if a tumor were near such
organs, it would disturb the evaluation of the TNR.
Conclusion
Despite variations in tumor pathology and a small patient
population, 18F-BPA accumulation in tumors showed a
strong correlation with 11C-Met accumulation. Thus, 11C-
Met PET/CT might be useful to select candidates for
18F-BPA PET/CT. However, 11C-Met PET/CT would not
be suitable for evaluating accumulation in some normal
organs, such as the submandibular gland, liver, heart,
stomach pancreas, spleen, and bone marrow. Therefore,
the 18F-BPA-PET study remains a prerequisite for BNCT.
However, further studies are called for, using larger num-
bers of participants and selection of particular histological
diagnostic criteria.
Limitations
As mentioned, some limitations should be acknowl-
edged. First, the very small population and retrospective
nature of this study may have led to selection bias.
Second, the study included a variety of tumor pathologies.
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